Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUIBRON-T/SR vs ELIXOMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
Treatment of symptoms and prevention of asthma,Treatment of reversible bronchospasm associated with chronic bronchitis and emphysema
Treatment of refractory epilepsy,Adjunctive therapy for complex partial seizures,Off-label: neuropathic pain management,Off-label: bipolar disorder maintenance
200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/m L). Maximum 800 mg/day.
500 mg orally once daily with a full glass of water, regardless of meals.
Terminal t1/2: 3-12 hours (adults); 1-9 hours (children); prolonged in cirrhosis (up to 30 hours), heart failure, elderly. Clinical context: Narrow therapeutic index (5-15 mcg/m L); dosing interval adjusted based on t1/2.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation. Saturable kinetics.
Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN.
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4): 90% to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid). Biliary/fecal: minimal (<5%).
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
~40% bound to albumin. Binding is reversible and non-saturable.
98% bound to albumin and alpha-1-acid glycoprotein.
Vd: 0.3-0.7 L/kg (adults); approximates total body water. Increased Vd in premature infants and obesity; decreased in dehydration.
0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding.
Oral: 100% (immediate-release); 90-100% for SR formulations (dose-dependent slightly lower).
Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: use 75% of normal dose, monitor levels. GFR <10 m L/min: use 50% of normal dose, monitor levels. Dose frequency unchanged.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg once daily; GFR 15-29 m L/min: 125 mg once daily; GFR < 15 m L/min or dialysis: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%, monitor levels. Child-Pugh C: reduce dose by 70%, monitor levels. Use immediate-release forms preferred.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended.
6-12 years: 10-16 mg/kg/day in divided doses every 12 hours (extended-release). 12-16 years: 12-18 mg/kg/day; target serum theophylline 5-15 mcg/m L. Maximum 800 mg/day.
Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established.
Initiate at lower end of dosing (200-400 mg/day). Monitor serum concentrations due to decreased clearance. Avoid doses >400 mg/day without level monitoring. Titrate cautiously.
No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if Cr Cl < 60 m L/min.
No FDA black box warning.
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
Seizures may occur at therapeutic levels,Use caution in patients with peptic ulcer, seizure disorders, cardiac arrhythmias,Monitor serum theophylline levels to avoid toxicity,Drug interactions with fluoroquinolones, cimetidine, macrolides, and allopurinol
Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation.
Hypersensitivity to theophylline or any component,History of seizure disorder (relative),Active peptic ulcer disease (relative)
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (Cr Cl <30 m L/min); pregnancy (teratogenic effects in animal studies).
Avoid charcoal-grilled meats and high-protein, low-carbohydrate diets which can decrease theophylline clearance. Caffeine-containing foods/beverages may potentiate adverse effects. Consistent dietary habits are recommended to maintain stable drug levels.
Grapefruit and grapefruit juice significantly increase ELIXOMIN plasma concentrations, increasing risk of toxicity. High-potassium foods (e.g., bananas, oranges, spinach) should be limited due to risk of hyperkalemia.
Theophylline (active ingredient) is not teratogenic in humans. First trimester: No increased risk of major malformations from epidemiological studies. Second/third trimester: No specific fetal risks; however, high maternal serum levels may cause neonatal toxicity (jitteriness, tachycardia) if near term.
ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Relative infant dose is less than 10% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for irritability or insomnia. Use lowest effective maternal dose.
Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity).
During pregnancy, theophylline clearance may decrease by 20-30% in third trimester due to reduced hepatic metabolism and increased volume of distribution. Monitor serum levels frequently and reduce dose by 10-20% if levels exceed therapeutic range; individualize dosing based on clinical response and drug monitoring.
Due to increased glomerular filtration rate (GFR) in pregnancy, higher doses of ELIXOMIN may be required to achieve therapeutic drug levels. However, given teratogenicity, use is contraindicated; alternative therapy should be considered.
Quibron-T/SR is a sustained-release theophylline formulation used for asthma and COPD. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L); levels >20 mcg/m L increase toxicity risk. Cimetidine, ciprofloxacin, and erythromycin decrease clearance, requiring dose reduction. Smoking induces metabolism, requiring higher doses. Use with caution in patients with heart failure, hepatic impairment, or fever.
Monitor serum potassium levels closely; ELIXOMIN can cause life-threatening hyperkalemia especially in patients with renal impairment. Avoid concurrent use with potassium-sparing diuretics.
Take exactly as prescribed; do not crush or chew sustained-release tablets.,Avoid excessive caffeine intake (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not stop abruptly; tapering may be needed.,Keep regular appointments for blood level monitoring.,Inform all healthcare providers of this medication.
Do not consume grapefruit or grapefruit juice while taking ELIXOMIN.,Take with food to reduce gastrointestinal upset.,Report any muscle cramps, palpitations, or irregular heartbeat immediately.,Avoid potassium supplements and salt substitutes containing potassium.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUIBRON-T/SR vs ELIXOMIN, answered by our medical review team.
QUIBRON-T/SR is a Xanthine Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.. ELIXOMIN is a Xanthine Bronchodilator that works by ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUIBRON-T/SR and ELIXOMIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUIBRON-T/SR is: 200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/m L). Maximum 800 mg/day.. The standard adult dose of ELIXOMIN is: 500 mg orally once daily with a full glass of water, regardless of meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUIBRON-T/SR and ELIXOMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUIBRON-T/SR is classified as Category C. Theophylline (active ingredient) is not teratogenic in humans. First trimester: No increased risk of major malformations from epidemiological studies. Second/third trimester: No sp. ELIXOMIN is classified as Category C. ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.